Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pericardial Effusion | 4 | 2019 | 118 | 0.920 |
Why?
|
| Pericardiocentesis | 2 | 2019 | 33 | 0.700 |
Why?
|
| Immunosuppressive Agents | 2 | 2014 | 1375 | 0.560 |
Why?
|
| Neoplasms | 12 | 2022 | 15193 | 0.500 |
Why?
|
| Cardiology | 2 | 2020 | 530 | 0.450 |
Why?
|
| Hypertension | 2 | 2014 | 1503 | 0.450 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 2195 | 0.450 |
Why?
|
| Cardiovascular System | 2 | 2018 | 145 | 0.430 |
Why?
|
| Cause of Death | 1 | 2015 | 752 | 0.420 |
Why?
|
| Antineoplastic Agents | 8 | 2019 | 14289 | 0.380 |
Why?
|
| Medical Oncology | 2 | 2020 | 1423 | 0.370 |
Why?
|
| Thromboembolism | 1 | 2010 | 155 | 0.350 |
Why?
|
| Blood Pressure | 1 | 2014 | 1467 | 0.320 |
Why?
|
| Ischemia | 1 | 2010 | 391 | 0.310 |
Why?
|
| Acute Coronary Syndrome | 2 | 2022 | 259 | 0.300 |
Why?
|
| Peripheral Arterial Disease | 1 | 2010 | 267 | 0.290 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 1756 | 0.260 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1360 | 0.230 |
Why?
|
| Thrombocytopenia | 2 | 2018 | 846 | 0.200 |
Why?
|
| Coronary Angiography | 3 | 2018 | 598 | 0.200 |
Why?
|
| Takayasu Arteritis | 1 | 2018 | 21 | 0.160 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 107 | 0.160 |
Why?
|
| Varenicline | 1 | 2018 | 65 | 0.150 |
Why?
|
| Brugada Syndrome | 1 | 2017 | 18 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 4757 | 0.150 |
Why?
|
| Nitroglycerin | 1 | 2017 | 43 | 0.150 |
Why?
|
| Echocardiography | 2 | 2020 | 1182 | 0.150 |
Why?
|
| Coronary Stenosis | 1 | 2018 | 117 | 0.150 |
Why?
|
| Cardiologists | 1 | 2017 | 33 | 0.150 |
Why?
|
| Nicotinic Agonists | 1 | 2018 | 113 | 0.150 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 687 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2019 | 577 | 0.140 |
Why?
|
| Pericarditis, Constrictive | 1 | 2016 | 11 | 0.140 |
Why?
|
| Central Venous Catheters | 1 | 2017 | 98 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2019 | 288 | 0.140 |
Why?
|
| Cardiac Tamponade | 1 | 2016 | 51 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 603 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 444 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 435 | 0.120 |
Why?
|
| Cardiotoxicity | 1 | 2015 | 155 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 501 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2022 | 6869 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2018 | 665 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2018 | 712 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 672 | 0.100 |
Why?
|
| Humans | 21 | 2022 | 261506 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4298 | 0.100 |
Why?
|
| Texas | 3 | 2019 | 6311 | 0.100 |
Why?
|
| Electrocardiography | 1 | 2017 | 1145 | 0.100 |
Why?
|
| Thrombosis | 1 | 2018 | 781 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2307 | 0.100 |
Why?
|
| Risk Factors | 5 | 2022 | 17523 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 884 | 0.090 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2010 | 37 | 0.090 |
Why?
|
| Heart | 1 | 2017 | 1223 | 0.090 |
Why?
|
| Thrombophilia | 1 | 2010 | 56 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 713 | 0.090 |
Why?
|
| Transfusion Reaction | 1 | 2010 | 102 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2010 | 205 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 14889 | 0.090 |
Why?
|
| Neurofibromatosis 1 | 1 | 2010 | 144 | 0.090 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 1011 | 0.080 |
Why?
|
| Amyloidosis | 1 | 2010 | 176 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 719 | 0.080 |
Why?
|
| Smoking | 1 | 2018 | 2440 | 0.080 |
Why?
|
| Heart Failure | 2 | 2019 | 2516 | 0.080 |
Why?
|
| Prognosis | 4 | 2019 | 21713 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2016 | 1471 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2017 | 1577 | 0.070 |
Why?
|
| Male | 11 | 2019 | 123000 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 2527 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 2104 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2019 | 37905 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6207 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 12221 | 0.070 |
Why?
|
| Time Factors | 2 | 2018 | 12926 | 0.060 |
Why?
|
| Quality of Life | 1 | 2019 | 4532 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 2927 | 0.060 |
Why?
|
| Female | 10 | 2022 | 141928 | 0.060 |
Why?
|
| Aged | 7 | 2019 | 70117 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2015 | 9180 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2017 | 3341 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2016 | 3518 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 767 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1411 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2015 | 9244 | 0.050 |
Why?
|
| Middle Aged | 6 | 2019 | 86204 | 0.050 |
Why?
|
| Adult | 5 | 2019 | 77950 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5319 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 3890 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2018 | 234 | 0.040 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2017 | 12 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 401 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 15694 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 32848 | 0.040 |
Why?
|
| Hematoma | 1 | 2018 | 160 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 2796 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2017 | 58 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2018 | 160 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2018 | 475 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2017 | 134 | 0.040 |
Why?
|
| Incidence | 2 | 2017 | 5673 | 0.040 |
Why?
|
| Counseling | 1 | 2018 | 381 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 750 | 0.030 |
Why?
|
| Aspirin | 1 | 2018 | 455 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2017 | 304 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 11538 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 354 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 329 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2017 | 270 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 2292 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 342 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 29902 | 0.030 |
Why?
|
| Adenine | 1 | 2016 | 631 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 12873 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2019 | 650 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 1035 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 4938 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 3842 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 1946 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4320 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 4758 | 0.020 |
Why?
|
| Sarcoma | 1 | 2017 | 1725 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6682 | 0.020 |
Why?
|